NewsBenzingaOppenheimer avvia la copertura su Amneal Pharmaceuticals con una valutazione di outperform, annuncia un obiettivo di prezzo di $27 Oppenheimer avvia la copertura su Amneal Pharmaceuticals con una valutazione di outperform, annuncia un obiettivo di prezzo di $27 Benzinga 2026.09.23 12:10 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Equal-Weight on Commercial Metals, Lowers Price Target to $63 Dow Falls Over 300 Points; Nvidia Posts Upbeat Earnings TD Cowen Maintains Hold on Calumet, Lowers Price Target to $37 If You Invested $100 In Cenovus Energy Stock 5 Years Ago, You Would Have This Much Today Wells Fargo Maintains Overweight on Cleveland-Cliffs, Raises Price Target to $18 TD Cowen Maintains Buy on BWX Technologies, Lowers Price Target to $180